Om rustig onder het genot van een kop koffie en een lange termijn visie te lezen:
Operational overview Q2 2017
Inflammation
? We reported the first interim readout with filgotinib in RA patients in long-term extension study DARWIN 3
at EULAR 2017: continued activity and safety in line with the core studies
1 Orkambi®
is a registered drug of Vertex Pharmaceuticals
THE GALAPAGOS GROUP
4
Galapagos NV • H1 Report 2017
? Our collaboration partner Gilead initiated new Phase 2 studies with filgotinib in cutaneous lupus
erythematosus, uveitis, and Sjögren’s syndrome
? We initiated Phase 2 studies with filgotinib in psoriatic arthritis and ankylosing spondylitis, initiation of
the former triggering a $10 million milestone payment from our collaboration partner Gilead
? We disclosed the target of GLPG1972 to be ADAMTS-5 during OARSI 2017
? We dosed the first osteoarthritis patient with GLPG1972 in a Phase 1b study in the U.S.
? We expect to report topline results with MOR106, a human monoclonal antibody targeting IL-17C, in a Phase
1b trial in atopic dermatitis patients later in 2017
? We nominated fully proprietary pre-clinical candidates GLPG3121 and GLPG3312 with undisclosed targets in
inflammation
Cystic fibrosis (CF)
? We reported favorable findings relating to safety and tolerability of C2 corrector GLPG2737 and potentiator
GLPG2451
? We reported initiation of the first triple combination patient program, starting with regulatory process in
July
? We reported plans to initiate patient studies with two additional triple combinations out of our deep CF
candidate portfolio
Idiopathic pulmonary fibrosis (IPF)
? We received orphan drug status from the U.S. FDA for GLPG1690 in IPF
? We completed the Phase 2a FLORA study with GLPG1690; we expect results in the third quarter
? We nominated fully proprietary pre-clinical candidate GLPG3499 in fibrosis, replacing GLPG2938
Additional pipeline progress
? We announced plans to initiate a new study with GPR84 inhibitor GLPG1205 in an undisclosed indication
later in 2017
? We nominated pre-clinical candidate GLPG2384 in an undisclosed indication
? We nominated pre-clinical candidate GLPG3535 for pain in the alliance with collaboration partner Calchan
Corporate
? We raised €364 million gross proceeds from a U.S. public offering and €4.7 million from warrant exercises,
resulting in the issue of 4,611,600 new shares
? We received shareholder approval for all proposed resolutions at the 25 April 2017 AGM and EGM
Recent events
? We announced the appointment of Michele Manto as SVP Commercial Operations
? On 27 July 2017, Servier announced the inlicensing of GLPG1972, triggering a €6 million license fee payment
to Galapagos